KdT Ventures Research Document
Overview
KdT Ventures is a premier early-stage frontier science venture capital firm founded in 2017 by Cain McClary, MD. The firm has established itself as the standard for supporting teams reimagining the molecular and physical layers of technology. With total assets under management exceeding $250 million across four funds, KdT has demonstrated sustained growth and investor confidence in its focused thesis around computational biology, synthetic chemistry, and applied physics.
Investment Thesis and Philosophy
KdT's core thesis centers on "reprogramming chemistry and biology using creative technology platforms" to solve humanity's greatest challenges. The firm operates at the intersection of deep science, rigorous technology, and venture investing. Rather than investing in incremental improvements, KdT targets frontier companies that are architecting the world at a molecular level—from gene therapy and synthetic biology to computational drug discovery and sustainable materials.
The firm's philosophy emphasizes long-term relationships with portfolio companies and deep technical understanding. Every partner at KdT brings substantial domain expertise, with team members holding MDs, PhDs, and experience as founders or operators in biotech and medtech. This allows the firm to evaluate cutting-edge science with credibility and provide substantive support beyond capital.
Stage Focus and Check Size
KdT is positioned as an early-stage investor, often providing the first institutional check into a company. The firm typically invests from pre-seed through Series A, with check sizes ranging from $500,000 to $5 million. The flexible approach to initial checks allows KdT to move quickly on exceptional science before traditional metrics are fully apparent. The firm explicitly states "the earlier the better" as its stage philosophy.
Fund IV ($100M, closed October 2024) represents the firm's largest fund to date. Previous fund history includes Fund I (closed 2018), Fund II ($50M, 2021), and Fund III ($80M, 2022). This progression reflects sustained LP confidence and growing capital deployment capability.
Portfolio Composition and Sectors
With 51 portfolio companies and 8 new investments in the last 12 months (as of late 2025), KdT has built a diversified frontier science portfolio. The firm invests across multiple sectors including:
Therapeutics & Gene Therapy: Dyno Therapeutics (AAV vectors), Terray Therapeutics (spatially encoded screening), Path AI (pathology AI), Azitra (live biotherapeutic products), STRM.BIO (extracellular vesicles)
Synthetic Biology & Bioengineering: Solugen (bio-based chemicals), Elegen (gene synthesis), Tierra Biosciences (cell-free systems), Andes (agricultural biology), Elemental Machines (lab automation)
Digital Health & Medical Devices: Abridge (clinical documentation AI), Theator (surgical guidance), Remedy Robotics (robotic surgery software), Braid Health (radiology AI)
Sustainable Materials & Climate: Checkerspot (designed materials from algae), PHNX Materials (sustainable concrete), MacroCycle (plastic recycling chemistry), Zymochem (bio-based polymers)
Agricultural & Food: Hi Fidelity Genetics (crop breeding), Elo Life Systems (agricultural gene editing)
Notable portfolio highlights include PathAI (Series C at $165M+), Solugen ($357M raised), and Dyno Therapeutics (gene therapy partnerships worth $1.8B+). The portfolio includes multiple companies founded by Stanford, MIT, and Harvard researchers.
Team & Decision-Making
KdT is led by co-founder and Managing Partner Cain McClary (MD, physician-scientist background). The team includes Phil Grayeski (Managing Partner, promoted Oct 2024, MD-PhD), Mack Healy (Partner, former startup attorney), Patrick Malone (Partner, MD-PhD in ML and neuroscience), Ketan Yerneni (Partner, physician-scientist), Blair Willette (Partner, PhD in Pharmacology), Yusuf Uddin (Partner, Head of Talent, PhD in Molecular Biophysics), and Kaitlyn Davis (Operations).
The team structure reflects a partnership model with distributed decision-making. The depth of scientific expertise across the team allows KdT to evaluate frontier science with credibility that traditional VCs cannot match.
Recent Activity & Fund Status
KdT is actively deploying capital. Recent press coverage (2023-2025) highlights strong portfolio performance:
- Terray Therapeutics: Multi-target collaboration with Bristol Myers Squibb (Dec 2023), NVIDIA investment for AI drug discovery (Nov 2023)
- Zymochem: $4M DOE award for bio-based polymers (Nov 2023)
- Azitra: $7.5M from Bayer partnership proceeds (June 2023)
- PathAI: Series C growth continuing
- Solugen: $357M raised (Sept 2021)
- Multiple portfolio exits and acquisitions (Circularis acquired by Ginkgo Bioworks, 2022)
Fund IV (Oct 2024) closed oversubscribed at $100M, signaling strong LP conviction and pipeline demand. The firm announced simultaneous promotions of two partners, indicating growth trajectory and succession planning.
Geographic & Investment Preferences
KdT is based in Austin, Texas with deep expertise in the Research Triangle region (Durham/Chapel Hill/Raleigh, NC) and connections to leading research institutions. The firm invests across the US and internationally. Portfolio companies span multiple geographies including US, Europe, and Israel.
The firm explicitly targets founders with deep domain expertise—scientists and engineers with relevant background in their target area. Ideal founders combine technical depth with ambition to tackle unsolved problems and commercialize breakthrough science.
Lead Tendency & Co-Investment Strategy
KdT typically leads or co-leads early-stage rounds as the first institutional investor. The firm actively builds relationships with other frontier science-focused investors (DCVC, Blackbird, and others) for follow-on syndicates. The fund's "first check" strategy gives KdT significant portfolio allocation and follow-on rights. The firm maintains reserves (approximately 50% per fund) for follow-on investments in successful portfolio companies.
Decision Timeline & Process
As an early-stage investor with deep scientific expertise, KdT can move quickly on quality opportunities. The partnership structure and in-house technical capability enable rapid due diligence. The firm emphasizes long-term relationships and mentor-style involvement with founders rather than purely financial returns optimization.
Content & Thought Leadership
KdT maintains an active content platform including:
- Substack newsletter: "The World In A Grain of Sand" (2,000+ subscribers) - deep dives on portfolio companies and frontier science trends
- Podcast: Features interviews with founders and deep science discussions
- Medium blog: Long-form content on investment philosophy and science commentary
This content positions KdT as thought leaders in frontier science investing and creates inbound founder flow from informed entrepreneurs.